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Abstract
In this paper, the performance of a control law designed for the automatic
administration of propofol and of remifentanil in order to track a desired
level for the bispectral index (BIS), used as a measure of the depth of anes-
thesia, is analyzed under the presence of model parameters uncertainties. It
is theoretically proved and illustrated by simulations that under these cir-
cumstances the controller has a very good performance as the BIS converges
to a value contained in a neighborhood of the desired BIS level. a retuning
strategy in order to improve the BIS tracking under the presence of uncer-
tainties was also theoretically deduced. Simulations show that this strategy
leads to BIS tracking improvement. The performance of the controller in
clinical environment is illustrated by a clinical case.
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1. Introduction
Correct administration of anesthesia drug is crucial for the success of surgery.
In this regard, the controllers developed for automatic administration of
drugs have to be extensively studied. It is important to study the perfor-
mance of the controller under the presence of modeling errors as the complex
nature of the human body and the inter- and intra-individual variability do
not allow obtaining an exact description of the drug e ect in each patient.
In this sense, it is also crucial to develop retuning techniques to calibrate the
controller in order to address possible misfits between the obtained results
and the desired values, arising not only from modeling errors, but also from
noisy measurements.
Here, the focus is the administration of the hypnotic propofol and of the
analgesic remifentanil. These drugs are used for the control of the depth of
anesthesia (DoA). The DoA is related to the intensity of two components
of general anesthesia: analgesia and hypnosis. According to several studies
(Tire´n et al. [1], Grindsta  and Tobias [2], Ekman et al. [3], Wodey et al.
[4], Whyte and Booker [5]) the DoA may be measured by means of the bis-
pectral index (BIS). This index is a single dimensionless number, which is
computed from the electroencephalogram (EEG) and ranges from 0 (equiva-
lent to EEG silence) to 100 (equivalent to fully awake and alert). According
to clinical experience, a BIS value between 40 and 60 is desirable for general
anesthesia purposes, as it usually corresponds to an adequate state of uncon-
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sciousness during surgical procedures. This is usually achieved manually by
the anesthesiologists. However, due to the high complexity of this procedure,
an automated system for drug administration would be a good support for
the clinicians. This question has deserved the attention of several researchers
and led to a number of contributions and controlleres namely a predictive
control in Ionescu et al. [6], an adaptive model-based controller in Mortier
et al. [7] and Simanski et al. [8], a PID in Padula et al. [9], a neural in Or-
tolani et al. [10], a fuzzy logic in Shieh et al. [11], a model predictive control
in Sawaguchi et al. [12] and Chang et al. [13]. but in these contributions the
control of the DoA is not fully automatic. More concretely, the administra-
tion of the hypnotic is made automatically, however the administration of
the analgesic is made manually by the anesthetic. A detailed introduction to
anesthesia as a control problem together with a good overview of the state
of the art can be found in Lemos et al. [14] and Dumont [15].
In Nogueira et al. [16] a control law was proposed for the BIS tracking of pa-
tients, during general anesthesia, by means of the automatic administration
of propofol and of refimentanil. This controller has the advantage of allowing
di erent combinations of drugs in order to obtain the same value for the BIS
level, it allows the changing of the desired reference value for the BIS during
the surgical procedure, and it is already used in clinical practices, with good
performance according to the anesthesiologists. The big difference between
this controller and the aforementioned controllers cited above is that: in the
referred works the BIS is controlled by the automatic administration of one
single drug (the hypnotic) together with the manual administration of the
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other drug (the analgesic), by the anesthesiologist, whereas in Nogueira et al.
[16] these two drugs are automatically administered, without any interven-
tion of the anesthesiologist.
The aim of this work is to study the performance of the controller proposed
in Nogueira et al. [16] under the presence of model parameters uncertain-
ties. It is theoretically proved that under these circumstances, the BIS level
converges to a value contained in a neighborhood of the desired BIS level.
This fact allows a retuning strategy in order to recalibrate the controller for
BIS tracking improvement. The theoretical deduction of this strategy is here
presented.
The structure of this paper is as follows. Section 2 is devoted to the ex-
planation of the BIS model, while the control law is presented in Section 3.
In Section 4 the robustness of the controller is analyzed and in Section 5 an
on-line retuning strategy is theoretically deduced. Simulations are illustrated
in Section 6 while a clinical case is presented in Section 7. Conclusions are
drawn in Section 8.
2. Model description
The patient BIS level obtained by means of the administration of the hypnotic
propofol and of the analgesic remifentanil may be modeled by a new Wiener
model recently introduced in the literature Silva et al. [17] and known as the
parameter parsimonious model (PPM). According to this model, the linear
relations between the propofol and remifentanil dosages and the correspond-
4
ing e ect concentrations (cpe and cre) are modeled by the transfer functions:
Hp(s) = k1k2k3–
3
(k1–+ s)(k2–+ s)(k3–+ s)
up(s), (1)
Hr(s) = l1l2l3÷
3
(l1÷ + s)(l2÷ + s)(l3÷ + s)
ur(s), (2)
respectively, where – and ÷ are patient dependent parameters, without any
explicit physiological meaning, k1, k2, k3 and l1, l2, l3 are dimensionless con-
stants whose values were identified in Silva et al. [17] from a real patient
database, as: k1 = 10, k2 = 9, k3 = 1, l1 = 3, l2 = 2, l3 = 1. The complex
functions up(s) and ur(s) are the Laplace transforms of the administered
doses of propofol, up(t), and of remifentanil, ur(t), in mgmin≠1. The corre-
sponding BIS level, z(t), usually given by the generalized Hill equation Minto
et al. [18], is approximated in Silva et al. [17] by the nonlinear equation:
z(t) = 97.71 + U“ , (3)
where U = µ c
p
e
ECp50
+ c
r
e
ECr50
, and µ and “ are patient dependent parameters,
without any physiological meaning, 97.7 is the BIS level at zero concentra-
tion, and ECp50 and ECr50 respectively denote the propofol and remifentanil
concentrations that produce half the maximal e ect when the drug acts in
isolation. The parameters ECp50 and ECr50 are taken to be fixed, namely
ECp50 = 10 mg/ml and ECr50 = 0.01 mg/ml. These values were obtained in
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the work developed in Mendonc¸a et al. [19].
The PPM may be also represented by the following state space represen-
tation:
Y_______________________]_______________________[
x˙(t) = Ax(t) +Bu(t)
SWU cpe(t)
cre(t)
TXV =
SWU 0 0 1 0 0 0
0 0 0 0 0 1
TXVx(t)
U(t) = Cx(t)
z(t) = 97.71 + U“ ,
(4)
where
6
C =
5
0 0 0.1µ 0 0 100
6
,
A =
SWU Ap 0
0 Ar
TXV , B =
SWU Bp 0
0 Br
TXV ,
Ap =
SWWWWWU
≠10– 0 0
9– ≠9– 0
0 – ≠–
TXXXXXV , Ar =
SWWWWWU
≠3÷ 0 0
2÷ ≠2÷ 0
0 ÷ ≠÷
TXXXXXV ,
Bp =
SWWWWWU
10–
0
0
TXXXXXV , Br =
SWWWWWU
3÷
0
0
TXXXXXV .
(5)
This specific form of the state space realization has compartmental struc-
ture. This has the advantage of allowing the use of the positive control law
defined in the next section.
3. Controller description
The nonlinear controller presented in Nogueira et al. [16] was designed for the
automatic administration of propofol and of remifentanil in order to control
the BIS level of a patient. This control law, which results from a combination
of a linear controller with a positivity constraint for the drug doses, is defined
by:
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u(t) =
SWU up(t)
ur(t)
TXV =
SWU max(0, u˜p(t))
max(0, u˜r(t))
TXV , (6)
where up is the input of propofol and ur is the input of remifentanil, with:
u˜(t) =
SWU u˜p(t)
u˜r(t)
TXV = E (≠KAx(t) + ⁄(Mú ≠Kx(t))) , (7)
and
E =
SWU ﬂ
1
TXV 1
–ﬂ+ 300÷ , (8)
Mú = 3(0.1ﬂ+ 100)0.1µﬂ+ 100
397.7
zú
≠ 1
4 1
“
, (9)
K =
5
0.1 0.1 0.1 100 100 100
6
, (10)
zú is the desired BIS level, and ⁄ and ﬂ are positive design parameters that do
not a ect the tracked reference value and can be chosen according to clinical
criteria. The parameter ⁄ influences the convergence speed to the desired
reference value and the parameter ﬂ can be interpreted as the proportion
between the doses of propofol and remifentanil.
For more details about this controller and its tracking properties, the reader
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is referred to Nogueira et al. [16].
The robustness of the controller (6) is analyze in the next section.
4. Controller robustnes in the presence of uncertainties in the lin-
ear part of the PPM
Here it will be proven that the controller (6) is robust under the presence
of uncertainties in the linear part of the PPM. More concretely, in this case,
the BIS of the patient will converge to a value contained in a neighborhood
of the desired reference for the BIS level. This is acceptable from the clinical
point of view, as, in clinical practice, the BIS level should be contained in an
interval, usually between 40 and 60.
Instead of the real values for the parameters – and ÷, estimates for those
values, –ˆ and ÷ˆ, are respectively used. This implies that instead of using
u as described in (11), for the automatic administration of propofol and of
remifentanil, the controller uˆ as described below is used.
uˆ(t) =
SWU uˆp(t)
uˆr(t)
TXV =
SWU max(0, ˆ˜up(t))
max(0, ˆ˜ur(t))
TXV , (11)
with:
ˆ˜u =
SWU ˆ˜up(t)
ˆ˜ur(t)
TXV = Eˆ 1≠KAˆx(t) + ⁄(Mú ≠Kx(t))2 , (12)
where
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Aˆ =
SWWWWWWWWWWWWWWWU
≠10–ˆ 0 0 0 0 0
9–ˆ ≠9–ˆ 0 0 0 0
0 –ˆ ≠–ˆ 0 0 0
0 0 0 ≠3÷ˆ 0 0
0 0 0 2÷ˆ ≠2÷ˆ 0
0 0 0 0 ÷ˆ ≠÷ˆ
TXXXXXXXXXXXXXXXV
, (13)
and
Eˆ =
SWU ﬂ
1
TXV 1
–ˆﬂ+ 300÷ˆ .
Defining
k = –ﬂ+ 300÷
–ˆﬂ+ 300÷ˆ , (14)
the matrix Eˆ may be written as:
Eˆ = Ek, (15)
and then ˆ˜u may be written as
ˆ˜u(t) = Ek
1
≠KAˆx(t) + ⁄(Mú ≠Kx(t))
2
. (16)
In the sequel, it is proven that when uˆ is applied to the PPM, as described
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in (4), the obtained BIS value converges to a steady state value in a neigh-
borhood of the desired BIS level. For this purpose, the auxiliary output
M(x) = Kx. (17)
is considered. 1
In particular, when M(x) converges to Mú (as in equation (9)), the BIS
level of the patient converges to the reference value zú.
Now, let:
 – = –≠ –ˆ, r = max{8–ˆ, ÷ˆ}, (19)
 ÷ = ÷ ≠ ÷ˆ, s = max{|8 –|, | ÷|}, (20)
and  KA = KA≠KAˆ,
and let:
IM =
Ë
M¯min , M¯max
È
, (21)
with
1This auxiliary output was used in Nogueira et al. [16], in the context of control without
model uncertainties, where it was proven that when M(x) converges to M¯ , the BIS level
converges to z¯, with
z¯ =
Qa 97.7
1 +
1
0.1µﬂ+100
3(0.1ﬂ+100)M¯
2“
Rb . (18)
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M¯min =
k⁄
k⁄+ ks
Mú, (22)
M¯max =
k⁄
k⁄≠ ksM
ú, (23)
 ks = |1≠ k|r + s. (24)
Applying the LaSalle’s invariance principle (see LaSalle [20]) to the Lyapunov
function V : Rn ≠æ R, described below, it is proven that M(x) converges
to IM .
V (x) =
Y_____]_____[
1
2(M(x)≠ M¯min)2 ifM(x) < M¯min
1
2(M(x)≠ M¯max)2 ifM(x) > M¯max
0 otherwise.
(25)
It will be shown next, by proving that V˙ (x) Æ 0, ’x œ Rn+, that the contin-
uous function V (x) is indeed a LaSalle-Lyapunov function of the system on
Rn+. For this, it has be taken into account that:
KAˆ = ≠
5
0.1–ˆ 0.1(8–ˆ) 0.1–ˆ 100÷ˆ 100÷ˆ 100÷ˆ
6
, (26)
 KA = (27)
≠
Ë
0.1 – 0.1(8 –) 0.1 – 100 ÷ 100 ÷ 100 ÷
È
,
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|KAˆ|x Æ rKx = rM(x), (28)
(29)
| KA|x Æ sKx = rM(x). (30)
Since
V˙ (x) =
Y_____]_____[
(M(x)≠ M¯min)M˙ ifM(x) < M¯min
(M(x)≠ M¯max)M˙ ifM(x) > M¯max
0 otherwise,
(31)
with M˙(x) = Kx˙ = KAx + KBuˆ, is defined piecewise, the analysis of the
non positivity of V˙ (x) into two cases has to be made. First it is considered
that M(x) < M¯min and it is proved that in this case M(x) > 0, implying
that V˙ < 0. Secondly, the case when M(x) > M¯max is studied. In particular,
M(x) < 0 and V˙ < 0 is verified.
Case one - M(x) < M¯min
When M(x) < M¯min, M(x) < Mú, and consequently ˆ˜u > 0. Then uˆ = ˆ˜u
and M˙(x) becomes:
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M˙(x) = KAx+KB ˆ˜u (32)
= KAx+KBE¸ ˚˙ ˝
1
k(≠KAˆx+ ⁄(Mú ≠M(x)) (33)
= KAx≠ kKAˆx+ k⁄(Mú ≠M(x))) (34)
= KAˆx+ KAx≠ kKAˆx+ k⁄(Mú ≠M(x)) (35)
= (1≠ k)KAˆx+ KAx+ k⁄(Mú ≠M(x)) (36)
Ø ≠|1≠ k||KAˆ|x≠ | KA|x+ k⁄(Mú ≠M(x)) (37)
Ø ≠|1≠ k|rM(x)≠ sM(x) + k⁄(Mú ≠M(x)) (38)
= ≠|1≠ k|rM(x)≠ sM(x) + k⁄Mú ≠ k⁄M(x) (39)
= k⁄Mú ≠ (k⁄+ |1≠ k|r + s)M(x) (40)
= k⁄Mú ≠ (k⁄+ ks)M(x) (41)
= (k⁄+ ks)
A
k⁄
k⁄+ ks
Mú ≠M(x)
B
(42)
= (k⁄+ ks)
1
M¯min ≠M(x)
2
> 0. (43)
The relation between expressions (36) and (37) is due to the fact that every
a œ R satisfies a Ø ≠|a|, whereas the relation between expressions (37) and
(38) results from (28) and (30).
Case two - M(x) > M¯max
Let M(x) > M¯max. If ˆ˜u < 0, then uˆ = 0 and
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M˙(x) = KAx (44)
= ≠
5
0.1– 0.8– 0.1– 100÷ 100÷ 100÷
6
x
Æ 0,
because all the components of x are nonnegative. If ˆ˜u > 0, then uˆ = ˆ˜u and
M˙(x) becomes (see equation (36)):
M˙(x) = (1≠ k)KAˆx+ KAx+ k⁄(Mú ≠M(x)) (45)
Æ |1≠ k||KAˆ|x+ | KA|x+ k⁄(Mú ≠M(x)) (46)
Æ |1≠ k|rM(x) + sM(x) + k⁄(Mú ≠M(x)) (47)
= |1≠ k|rM(x) + sM(x) + k⁄Mú ≠ k⁄M(x) (48)
= k⁄Mú ≠ (k⁄≠ |1≠ k|r ≠ s)M(x) (49)
= k⁄Mú ≠ (k⁄≠ ks)M(x) (50)
= (k⁄≠ ks)
A
k⁄
k⁄≠ ksM
ú ≠M(x)
B
(51)
= (k⁄≠ ks)
1
M¯max ≠M(x)
2
< 0, (52)
for k⁄ > | ks|.
Hence, it may been concluded that choosing the parameter ⁄ large enough,
such that ⁄ > | ks|k , V˙ (x) is non positive during all time. Then, by the
LaSalle’s invariance principle, all system trajectories, x(t), converge to the
largest set contained in
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W = {x œ Rn+ : V˙ (x) = 0}, (53)
which is forward-invariant under the closed-loop dynamics. It follows from
(31) that V˙ (x) = 0 either when u = u˜ and (M(x) = M¯min or M(x) = M¯max
orM(x) = (1≠k)KAˆx+ KAx+k⁄Múk⁄ ), or when u = 0, which implies thatM(x) >
Mú, and KAx = 0. Then
W =I1 ﬁ I2 ﬁ I3 ﬁ I4 with (54)
I1 ={x œ Rn+ : M(x) = M¯min and ˆ˜u(x) > 0} (55)
I2 ={x œ Rn+ : M(x) = M¯max and ˆ˜u(x) > 0} (56)
I3 ={x œ Rn+ : M(x) =
(1≠ k)KAˆx+ KAx
k⁄
+Mú and ˆ˜u(x) > 0} (57)
I4 ={x œ Rn+ : KAx = 0 and uˆ(x) = 0}. (58)
The set I4 is not invariant. In fact, if uˆ would remain equal to zero, at a
certain time instant, M(x) would become smaller than Mú, ˆ˜u(x) would be-
come positive, and uˆ(x) would equal ˆ˜u(x), so the trajectory x(t) would leave
the subset. On the other hand, both I1, I2 and I3 are subsets of IM , which
is invariant, indeed if M(x) Æ M¯min, then M˙(x) Ø 0 and if M(x) Ø M¯max,
then M˙(x) Æ 0. Therefore, one may conclude that M(x) converges to (a
subset contained in) the interval IM as previously claimed.
Since the patient BIS response to the administered drug doses uˆ is a de-
creasing function of M(x) (cf. equation (18)), the BIS level converges to the
interval:
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IBIS = ]BISmin , BISmax[ , (59)
with
BISmin =
97.7
1 +
1
0.1µﬂ+100
3(0.1ﬂ+100)M¯max
2“ and (60)
(61)
BISmax =
97.7
1 +
1
0.1µﬂ+100
3(0.1ﬂ+100)M¯min
2“ . (62)
As expected, the desired steady state value zú is not achieved, but the pa-
tient’s BIS remains in a neighborhood of this target value. Moreover, when
the errors in the parameters go to 0, and hence s goes to 0 and k goes to 1
(see the remark below), M¯min, M¯max andM(x) converge toMú. This implies
that the patient BIS converges to the desired value zú, which means that the
control law is robust with respect to parameter uncertainties. Moreover, as
can be seen by expressions (22) and (23), increasing the parameter ⁄ de-
creases the width of the interval IM and consequentely the robustness of the
controller is also increased.
Note that:
k =–ﬂ+ 300÷
–ˆﬂ+ 300÷ˆ (63)
= –ˆﬂ+ –ﬂ+ 300÷ˆ + 300 ÷
–ˆﬂ+ 300÷ˆ (64)
=1 +  –ﬂ+ 300 ÷
–ˆﬂ+ 300÷ˆ , (65)
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thus, if  – and  ÷ converge to zero k clearly converges to the value 1.
As it shall be next proven, in the presence of uncertainties in the PPM
linear part, the BIS of the patient not only remains in the interval IBIS, but
also converges to a specific value z¯ œ IBIS.
5. Retuning improvement in the presence of uncertainties in the
PPM linear part
In Nogueira et al. [21], a retuning strategy was proposed in order to over-
come the discrepancy between the obtained BIS level for the patient and
the desired one. As already mentioned this may be the result of modeling
errors and measurement noise. This strategy consists of computing another
reference value for Mú in (7), by assuming that, in spite of the presence of
modeling errors, the BIS converges to a determined value and assuming also
that there is a proportion between the obtained BIS value and the reference
value Mú.
Here the specific case where the misfit between the desired BIS value and
the obtained one is due to the presence of errors in the PPM linear part
parameters is analyzed. Moreover, it is theoretically proven that the patient
BIS indeed converges to a specific value z¯, which allows the computation
of a new reference for Mú for recalibration of the control law (16). More
concretely, it will be proven that the auxiliary output M(x) will converge
to a value M¯ , which is equivalent to have the BIS converging to the value
z¯ =
A
97.7
1+( 0.1µﬂ+1003(0.1ﬂ+100)M¯)“
B
, and then the controller is retuning based on the BIS
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obtained.
In order to prove that M(x) converges to a value M¯ , it will be first proved
that after a certain instant tÁ, ˆ˜u will remain nonnegative. Then, it will be
proved that, in this case, there is only one equilibrium point. After finding
the equilibrium point the controller may be recalibrated.
Prove that: ’t Ø tÁ, ˆ˜u(t) Ø 0.
Let Á Ø 0. It is intended to prove that ’Á Ø 0,÷tÁ Ø 0 : ˆ˜u(tÁ) Ø 0.
In the previous section, it was proved that under the presence of uncer-
tainties in the linear part of the PPM, the auxiliary output M(x) remains in
the interval IM , i.e.,
M(x) œ IM =
Ë
M¯min , M¯max
È
. (66)
Thus, for every Á Ø 0:
M(x) œ IM =
Ë
M¯min ≠ Á , M¯max + Á
È
. (67)
Note that
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ˆ˜u Ø 0 (68)
… Ek¸˚˙˝
>0
(≠KAˆx+ ⁄(Mú ≠M(x)) Ø 0 (69)
… ≠KAˆx+ ⁄Mú ≠ ⁄M(x) Ø 0 (70)
… KAˆx+ ⁄M(x) Æ ⁄Mú. (71)
By (28), the following inequalities hold
KAˆx+ ⁄M(x) Æ rM(x) + ⁄M(x) (72)
= (r + ⁄)M(x) (73)
< rM(x) (74)
< r(M¯max + Á). (75)
Consider (see (71) and (75)):
r(M¯max + Á) Æ ⁄Mú, (76)
which is equivalent to
Á Æ ⁄M
ú
r
≠ M¯max. (77)
Thus, for t Ø tÁ, ⁄ > 0 and Á = ⁄M
ú
r
≠ M¯max, ˆ˜u(t) Ø 0.
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Prove that for all t Ø tÁ, there is one equilibrium point.
According to the demonstration conducted above, there exists a certain in-
stant tÁ > 0, such that for t Ø tÁ, uˆ(t) = ˆ˜u(t) Ø 0. Thus, for t Ø tÁ,
M˙(x) = 0… (78)
Kx˙ = 0… KAx+KBE¸ ˚˙ ˝
=1
k(≠KAˆx+ ⁄(Mú ≠M(x))) = 0 (79)
… KAx≠ kKAˆx+ k⁄Mú ≠ k⁄M(x) = 0 (80)
… ≠KAx+ kKAˆx+ k⁄M(x) = k⁄Mú (81)
and
ˆ˜u =E(≠kKAˆx+ k⁄Mú ≠ k⁄M(x)) (82)
=E(≠kKAˆx≠KAx+ kKAˆx+ k⁄M(x)≠ k⁄M(x)) [ by (81) ] (83)
=≠ EKAx. (84)
When M(x) = Mú, i.e, when M˙ = 0, the control uˆ is then given by ˆ˜u =
≠EKAx, and the closed-loop system can be described by
x˙ = (A≠BEKA)x. (85)
In Nogueira et al. [16] it was shown that the system (85) is stable with the
equilibrium point, xeq, described by:
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xeq =
SWWWWWWWWWWWWWWWU
ﬂ
ﬂ
ﬂ
1
1
1
TXXXXXXXXXXXXXXXV
cre, (86)
where cre is the e ect concentration of remifentanil.
Thus, by (81) and (86), the solution of the systemY_]_[ Ax+Buˆ = 0M˙(x) = 0 (87)
is computed by the following equation:
≠KA
SWWWWWWWWWWWWWWWU
ﬂ
ﬂ
ﬂ
1
1
1
TXXXXXXXXXXXXXXXV
c¯re + kKAˆ
SWWWWWWWWWWWWWWWU
ﬂ
ﬂ
ﬂ
1
1
1
TXXXXXXXXXXXXXXXV
c¯re + k⁄K
SWWWWWWWWWWWWWWWU
ﬂ
ﬂ
ﬂ
1
1
1
TXXXXXXXXXXXXXXXV
c¯re = k⁄Mú (88)
which is equivalent to:
c¯re = SMú, (89)
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for suitable S, that may be determined by observing the BIS value of the
patient. More concretely, and noting that the value of Mú is known, after
the e ect concentration of remifentanil, c¯re, be computed by inverting the Hill
equation, S may be determine by the following expressions:
S = c¯
r
e
Mú
(90)
= U¯0.1µﬂ+ 100
1
Mú
(91)
=
1
97.7
z¯ ≠ 1
2 1
“
0.1µﬂ+ 100
1
Mú
, (92)
where z¯ is the BIS of the patient and U¯ is the corresponding potency.
In order to improve the convergence of the BIS, the reference value Mú in
the controller (16) is replaced for another reference value Múú. The reference
Múú must be such that the e ect concentration of remifentanil, ¯¯cre, obtained
by using it would be equal to the desired e ect concentration of remifentanil,
crúe , i.e., the following equality must hold:
¯¯cre = crúe =
Mú
3(0.1ﬂ+ 100) . (93)
By (89), this would be equivalent to:
¯¯cre = SMúú =
Mú
3(0.1ﬂ+ 100) . (94)
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Which means that
Múú = 1
S
Mú
3(0.1ﬂ+ 100) (95)
= 0.1µﬂ+ 1001
97.7
z¯ ≠ 1
2 1
“
Mú
Mú
3(0.1ﬂ+ 100) (96)
= 11
97.7
z¯ ≠ 1
2 1
“
Mú
0.1µﬂ+ 100
3(0.1ﬂ+ 100)M
ú (97)
=
1
97.7
zú ≠ 1
2 1
“1
97.7
z¯ ≠ 1
2 1
“
Mú. (98)
Concluding, in the presence of uncertainties in the linear part of the PPM,
the BIS of the patient will converge to a certain value z¯, instead of converging
to the desired one zú. This problem may be overcome, by observing the BIS
at steady-state, z¯, and retuning the control law replacing the reference value
Mú for the new reference value Múú computed as in (98).
It is noteworthy that the formula (98) here deduced to compute the reference
Múú is the same as the one proposed in Nogueira et al. [21]. This is due to
the fact that, although it was not proved in the work presented in Nogueira
et al. [21], it was assumed that the BIS converges to a single value and that
there is a proportion between the obtained BIS value z¯ and the reference BIS
valueMúú, which actually happens when there are errors in the identification
of the parameters of the linear part of the PPM, as it was proved in this work.
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Remark 5.1. In clinical practice, sometimes the reference value for the BIS
must be changed during surgery. The control law (6) allows this changing
by computing another value for Mú to be used in the controller, i.e., it is
computed Mú = M ref2mod =
3(0.1ﬂ+ 100)
0.1µﬂ+ 100
“
Û
z0
zú2
≠ 1, where zú2 is the new refer-
ence value for the BIS. In case there is a misfit in the BIS response, a new
retuning for the Mú value is necessary in order to achieve the new desired
reference value for the BIS, which may delay reference tracking. An alterna-
tive to overcome this drawback is to immediately use a retuned value for Mú,
given by
Mú =
1
97.7
zú ≠ 1
2 1
“1
97.7
z¯ ≠ 1
2 1
“
M ref2mod . (99)
This corresponds to using equation (98), with Mú replaced by the new refer-
ence value M ref2mod .
6. Simulations
In this section, the performance of the controller (6), proposed in Nogueira
et al. [16], under the presence of uncertainties in the parameters of the linear
part of the PPM and the performance of the retuning strategy here proposed
are illustrated by means of simulations. Note that although the presented
models and control law are in continuous time, they are discretized for im-
plementation (by means of a zoh).
The simulated patients were set up based on the data of real patients sub-
jected to general anesthesia under propofol and remifentanil administration.
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The DoA was monitored by the BIS level and was manually controlled around
clinically accepted values by the anesthetist. Alaris GH pumps were used for
both propofol and remifentanil. Infusion rates, BIS values and other physio-
logical variables were acquired every five seconds (Mendonc¸a et al. [19]).
In Figure 1 the BIS evolution of a patient is illustrated where the test pa-
tient was considered to be modeled by a PPM with realistic parameters:
– = 0.086, ÷ = 0.021, µ = 1.42, and “ = 0.98 (see Mendonc¸a et al. [19]). On
the other hand, the control law (11) was tuned with the design parameters
⁄ = 100 and ﬂ = 900, and was tuned for the estimated parameters –ˆ = 50–
and ÷ˆ = 50÷. The desired reference value for the BIS, zú, was set to be 50.
As theoretically proved, the BIS converged to a value z¯ that belongs to the
interval
IBIS = ]BISmin , BISmax[ , (100)
with BISmin = 42 and BISmax = 56. As it may observed, in Figure 1,
the BIS response of the patient converged to 54 rather than to the desired
reference value, zú = 50, i.e., the BIS was a ected by an error of 8%. The
new reference Mú was computed, as in (98), at time t0 = 40 min, improving
the BIS response of this patient, which converged to 48.5 representing an
error of 3%.
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Figure 1: BIS evolution in the presence of uncertainties, –ˆ = 50–, ÷ˆ = 50÷.
The reference value for the BIS level was set to be 50.
In order to test the performance of the retuning strategy under more ad-
verse circumstances, six patients are simulated by six PK/PD Wiener mod-
els (other than the PPM) described in Appendix A. The nonlinear part
was taken to coincide with the generalized Hill equation (3) and the corre-
sponding parameters “ and µ were identified in Mendonc¸a et al. [19] from
the surgery data (see Table B.3). The values of ECp50 and ECr50 are re-
spectively 10 mg/ml and 0.01 mg/ml, as previously mentioned. It was also
added to the BIS signal Gaussian white noise with zero mean and standard
deviation ‡noise = 3. In order to improve the performance of the control
procedure in the presence of noise, a filter was applied to the noisy BIS sig-
nal. The misfit in the nonlinear part of the patient model was also increased.
More concretely, instead of the values “ and µ, identified for the six patients
(see Table B.3), other values for “ and µ were chosen in the PPM, namely
“ = 1.88 and µ = 1.79. These values are the average of the values for “ and
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µ taken from a bank of identified values for eighteen real patients obtained
in the work developed in Mendonc¸a et al. [19]. As can be seen in Fig. 2
even in this adverse circumstance, the control of the BIS of the patient, with
the retuning strategy applied at time instant t = 30 min also improved the
tracking of the desired reference value, which was set to be 50, zú = 50, and
was a success from the clinical point of view, more concretely, 100% of the
BIS value obtained were within 40 and 60, as desired.
The performance of the retuning strategy was also tested under extreme
adversities. One hundred patients were simulated with PK/PD Wiener mod-
els (other than the PPM) described in Appendix A and were controlled
with the control law as described in Nogueira et al. [16], using the PPM. In
order to increase the misfit between the patient model and the PPM (used in
the controller), the parameters –, ÷, µ and “ were not identified. Instead, we
tune the controller with – = 0.0759, ÷ = 0.5825, µ = 1.79 and “ = 1.88, for
all the one hundred simulations. These values are the average values from a
bank of eighteen real patients identified in Mendonc¸a et al. [19]. It was also
added to the BIS signal Gaussian white noise with zero mean and standard
deviation ‡noise = 3. A filter was then applied to the noisy BIS signal. The de-
sired reference value was set to be 50, zú = 50, and the retuning strategy was
applied at time instant t = 30 min. The application of the retuning strategy
improved the tracking of the desired reference value in 100% of the cases,
as theoretically expected. Moreover, the BIS obtained after the controller
retuning was within 40 and 60 in 100% of the cases, as clinically desired. The
results of these simulations are illustrated in Fig. 3.
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Figure 2: BIS evolution, in the presence of noise, of 6 patients modeled by a
PK/PD model with a retuning strategy applied at instant t = 30 min. The
desired BIS level is set to be 50.
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Figure 3: BIS evolution, in the presence of noise, of 100 patients modeled
by a PK/PD model with a retuning strategy applied at instant t = 30 min.
The desired BIS level is set to be 50.
7. Clinical case
In this section, a clinical case is presented where the administration of propo-
fol and remifentanil was automatically made by using the controller proposed
in Nogueira et al. [16], integrated in the Galeno platform (Costa et al. [22]).
This platform was developed in the framework of the portuguese funding
agency (FCT) project Galeno, and incorporates several identification and
control procedures for automation in anesthesia. This supervisory automatic
drug administration system is currently implemented in a surgery room at
the ULSM (Pedro Hispano Hospital, Matosinhos, Portugal), where the data
here presented were collected, under medical surveillance. Manual drug ad-
ministration is ready to be switched on both under clinical decision or in
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case of failure of the automatic controller. The patient, a man of 85 years of
age, 80kg of weight and 1.72m of height was subject to general anesthesia,
for a partial gastrectomy. Alaris GH pumps were used for both propofol and
remifentanil. Infusion rates, BIS values and other physiological variables were
acquired with a sampling time of five seconds. The neuromuscular blockade
(NMB) was controlled manually by bolus administration.
Due to clinical constraints associated to the anesthetic procedures adjusted
to the patient and also for clinical constraints, the controller was not started
at the beginning of the anesthetic procedure.
In Figure 4 a summary of the global situation that highlights the main fea-
tures of the controller and the relevant anesthetics clinical data during the
surgery is presented. The time for initialization of the automatic controller
was defined by the anesthetists and is marked with a red arrow.
The desired BIS level was initially set to be 50 and was changed along
the surgery (at time instants: t1 = 8 min, t2 = 47 min, t3 = 55 min,
t4 = 95 min), due to clinical directives. As it can be observed, the automatic
controller presented an adequate clinical behavior leading to the desired ref-
erence tracking.
According to the anesthesiologists, the performance of the controller is con-
sidered to be satisfactory.
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Figure 4: Partial printout of the final report of the clinical case. The dashed
blue row on the top graph corresponds to the desired reference value for the
BIS. The top red arrow marks the initialization of the automatic control. The
NMB plot should be disregarded, as this feature is being manually controlled.
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8. Conclusion
In this paper, the performance of a nonlinear controller, proposed recently in
the literature, for automatic administration of propofol and of remifentanil
in order to control the BIS of a patient, was analyzed. Here, it was theoret-
ically proven that under the presence of uncertainties in the parameters of
the linear part of the BIS model, the BIS of the patient converges to a value
that is contained in a neighborhood of the desired BIS level. A retuning
strategy to recalibrate the controller in order to improve the BIS tracking
under the presence of uncertainties was also theoretically deduced. The ro-
bustness theoretical analysis and the performance of the retuning strategy
here proposed were illustrated by simulations. Moreover, the performance of
the controller in clinical practice was also illustrated. Both the simulations
and the clinical case have shown that the controller has a good performance
under the presence of parameter uncertainties and that the retuning strategy
here proposed improves the tracking for the desired reference. These results,
together with the positive global assessment of the anesthesiologists concern-
ing the controller features, constitute a strong encouragement to consider the
proposed controller as good option for use in clinical environment.
Appendix A. PK/PD Model Description
The e ect concentration of propofol (cpe) and of remifentanil (cre) can be
modeled by the PK/PD state space models given in Ionescu et al. [23], based
on the material presented in Bailey and Haddad [24], Marsh et al. [25], Minto
et al. [26], and Schnider et al. [27], which have the following form:
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Y_]_[
x˙i = Aixi +Biui
cie =
5
0 0 0 1
6
xi,
(A.1)
where
i = p, r; p stands for propofol and r stands for remifentanil,
xi =
SWWWWWWWWU
xi1
xi2
xi3
xi4
TXXXXXXXXV
,
Ai =
SWWWWWWWWU
≠ki10 ≠ ki12 ≠ ki13 ki21V i2/V i1 ki31V i3/V i1 0
ki12V
i
1/V
i
2 ≠ki21 0 0
ki13V
i
1/V
i
3 0 ≠ki31 0
kie0 0 0 ≠kie0
TXXXXXXXXV
,
Bi =
SWWWWWWWWU
1
V i1
0
0
0
TXXXXXXXXV
(A.2)
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with, for the case of propofol (i=p):
V i1 = 4.27 [l]
V i2 = 18.9≠ 0.391(age≠ 53) [l]
V i3 = 238 [l]
Ci1 = 1.89 + 0.0456(weight≠ 77)≠ 0.0681(lbm≠ 59) + 0.0264(height≠ 177) [l/m]
Ci2 = 1.29≠ 0.024(age≠ 53) [l/m]
Ci3 = 0.836 [l/m]
Kie0 = 0.456 [min≠1]
Ki10 =
Ci1
V i1
[min≠1]
Ki12 =
Ci2
V i1
[min≠1]
Ki13 =
Ci3
V i1
[min≠1]
Ki21 =
Ci2
V i2
[min≠1]
Ki31 =
Ci3
V i3
[min≠1]
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and, for the case of remifentanil (i=r):
V i1 = 5.1≠ 0.0201(age≠ 40) + 0.072(lbm≠ 55) [l]
V i2 = 9.82≠ 0.0811(age≠ 40) + 0.108(lbm≠ 55) [l]
V i3 = 5.42 [l]
Ci1 = 2.6≠ 0.0162(age≠ 40) + 0.0191(lbm≠ 55) [l/m]
Ci2 = 2.05≠ 0.0301(age≠ 40) [l/m]
Ci3 = 0.076≠ 0.00113(age≠ 40) [l/m]
Kie0 = 0.595≠ 0.007(age≠ 40) [min≠1]
Ki10 =
Ci1
V i1
[min≠1]
Ki12 =
Ci2
V i1
[min≠1]
Ki13 =
Ci3
V i1
[min≠1]
Ki21 =
Ci2
V i2
[min≠1]
Ki31 =
Ci3
V i3
[min≠1]
The lean body mass (lbm) for women and men are computed, respectively,
by the equations
1.07weight≠ 148weight
2
height2
and 1.1weight≠ 128weight
2
height2
. (A.3)
Appendix B. Database
This database was courteously provided by Galeno project (http://www2.fc.up.pt/galeno/).
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The parameters presented in Table B.2 were identified in Mendonc¸a et al.
[19].
Table B.1: Patient features
Gender Age Height (cm) Weight (kg)
Patient 1 F 56 160 88
Patient 2 F 64 146 60
Patient 3 F 29 163 59
Patient 4 F 51 163 55
Patient 5 F 68 158 113
Patient 6 F 66 155 74
Table B.2: PPM parameters
– ÷
Patient 1 0.0667 0.3989
Patient 2 0.0489 0.1269
Patient 3 0.0737 0.2793
Patient 4 0.0701 0.2837
Patient 5 0.0687 4.5413
Patient 6 0.1336 0.2307
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Table B.3: PK/PD model parameters - Hill eq.
“ µ
Patient 1 2.0321 4.3266
Patient 2 1.0702 3.9505
Patient 3 3.7297 4.1494
Patient 4 1.8645 3.8367
Patient 5 0.9882 3.8094
Patient 6 1.5613 4.2411
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